Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03633227




Registration number
NCT03633227
Ethics application status
Date submitted
8/04/2018
Date registered
16/08/2018
Date last updated
6/09/2022

Titles & IDs
Public title
Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment
Scientific title
A Phase 4, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Pharmacokinetics and Safety of Obeticholic Acid in Patients With Primary Biliary Cholangitis and Moderate to Severe Hepatic Impairment
Secondary ID [1] 0 0
747-401
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Liver Cirrhosis, Biliary 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Infection 0 0 0 0
Other infectious diseases
Inflammatory and Immune System 0 0 0 0
Connective tissue diseases
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Obeticholic Acid (OCA)
Treatment: Drugs - Placebo

Experimental: Obeticholic Acid (OCA) - Participants will initiate treatment with OCA 5 milligrams (mg) tablets orally once weekly. At Week 12, if there are no safety concerns, the dose will be up-titrated to OCA 5 mg twice weekly. Every 6 weeks thereafter, based on tolerability assessments, further up-titration of dose will be considered. At each titration visit, the participants will start the higher dose regimen no earlier than 2 days after the prior dose. The maximum dose titration will be OCA 10 mg twice weekly at least 3 days apart. The minimum treatment duration will be 48-weeks. Participants, who complete their 48-week treatment, can continue the treatment until all randomized participants complete their 48-week treatment period and the database for that period is locked (total duration: approximately up to 3 years).

Placebo comparator: Placebo - Participants will receive OCA matching placebo orally once weekly or twice weekly for the duration of at least 48-weeks. Participants, who complete their 48-week treatment, can continue the treatment until all randomized participants complete their 48-week treatment period and the database for that period is locked (total duration: approximately up to 3 years).


Treatment: Drugs: Obeticholic Acid (OCA)
OCA will be administered per dose and schedule specified in the arm description.

Treatment: Drugs: Placebo
OCA matching placebo will be administered per the schedule specified in the arm description.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Maximum Observed Concentration (Cmax) of Total OCA at Week 12
Timepoint [1] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 12
Primary outcome [2] 0 0
Time to Maximum Concentration (Tmax) of Total OCA at Week 12
Timepoint [2] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 12
Primary outcome [3] 0 0
Trough Concentration (Ctrough) of Total OCA at Week 12
Timepoint [3] 0 0
24 hours post-dose at Week 12
Primary outcome [4] 0 0
Area Under the Concentration Versus Time Curve From Zero Time to 24 Hours (AUC0-24h) of Total OCA at Week 12
Timepoint [4] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 12
Primary outcome [5] 0 0
Cmax of Total OCA at Week 18
Timepoint [5] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 18
Primary outcome [6] 0 0
Tmax of Total OCA at Week 18
Timepoint [6] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 18
Primary outcome [7] 0 0
Ctrough of Total OCA at Week 18
Timepoint [7] 0 0
24 hours post-dose at Week 18
Primary outcome [8] 0 0
AUC0-24h of Total OCA at Week 18
Timepoint [8] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 18
Primary outcome [9] 0 0
Cmax of Total OCA at Week 24
Timepoint [9] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 24
Primary outcome [10] 0 0
Tmax of Total OCA at Week 24
Timepoint [10] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 24
Primary outcome [11] 0 0
Ctrough of Total OCA at Week 24
Timepoint [11] 0 0
24 hours post-dose at Week 24
Primary outcome [12] 0 0
AUC0-24h of Total OCA at Week 24
Timepoint [12] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 24
Primary outcome [13] 0 0
Cmax of Total OCA at Week 30
Timepoint [13] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 30
Primary outcome [14] 0 0
Tmax of Total OCA at Week 30
Timepoint [14] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 30
Primary outcome [15] 0 0
Ctrough of Total OCA at Week 30
Timepoint [15] 0 0
24 hours post-dose at Week 30
Primary outcome [16] 0 0
AUC0-24h of Total OCA at Week 30
Timepoint [16] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 30
Primary outcome [17] 0 0
Cmax of Total OCA at Week 48
Timepoint [17] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 48
Primary outcome [18] 0 0
Tmax of Total OCA at Week 48
Timepoint [18] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 48
Primary outcome [19] 0 0
Ctrough of Total OCA at Week 48
Timepoint [19] 0 0
24 hours post-dose at Week 48
Primary outcome [20] 0 0
AUC0-24h of Total OCA at Week 48
Timepoint [20] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 48
Primary outcome [21] 0 0
Cmax of Unconjugated OCA at Week 12
Timepoint [21] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 12
Primary outcome [22] 0 0
Tmax of Unconjugated OCA at Week 12
Timepoint [22] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 12
Primary outcome [23] 0 0
Ctrough of Unconjugated OCA at Week 12
Timepoint [23] 0 0
24 hours post-dose at Week 12
Primary outcome [24] 0 0
AUC0-24h of Unconjugated OCA at Week 12
Timepoint [24] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 12
Primary outcome [25] 0 0
Cmax of Unconjugated OCA at Week 18
Timepoint [25] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 18
Primary outcome [26] 0 0
Tmax of Unconjugated OCA at Week 18
Timepoint [26] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 18
Primary outcome [27] 0 0
Ctrough of Unconjugated OCA at Week 18
Timepoint [27] 0 0
24 hours post-dose at Week 18
Primary outcome [28] 0 0
AUC0-24h of Unconjugated OCA at Week 18
Timepoint [28] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 18
Primary outcome [29] 0 0
Cmax of Unconjugated OCA at Week 24
Timepoint [29] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 24
Primary outcome [30] 0 0
Tmax of Unconjugated OCA at Week 24
Timepoint [30] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 24
Primary outcome [31] 0 0
Ctrough of Unconjugated OCA at Week 24
Timepoint [31] 0 0
24 hours post-dose at Week 24
Primary outcome [32] 0 0
AUC0-24h of Unconjugated OCA at Week 24
Timepoint [32] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 24
Primary outcome [33] 0 0
Cmax of Unconjugated OCA at Week 30
Timepoint [33] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 30
Primary outcome [34] 0 0
Tmax of Unconjugated OCA at Week 30
Timepoint [34] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 30
Primary outcome [35] 0 0
Ctrough of Unconjugated OCA at Week 30
Timepoint [35] 0 0
24 hours post-dose at Week 30
Primary outcome [36] 0 0
AUC0-24h of Unconjugated OCA at Week 30
Timepoint [36] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 30
Primary outcome [37] 0 0
Cmax of Unconjugated OCA at Week 48
Timepoint [37] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 48
Primary outcome [38] 0 0
Tmax of Unconjugated OCA at Week 48
Timepoint [38] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 48
Primary outcome [39] 0 0
Ctrough of Unconjugated OCA at Week 48
Timepoint [39] 0 0
24 hours post-dose at Week 48
Primary outcome [40] 0 0
AUC0-24h of Unconjugated OCA at Week 48
Timepoint [40] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 48
Primary outcome [41] 0 0
Cmax of Glyco Conjugate of OCA (Glyco-OCA) at Week 12
Timepoint [41] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 12
Primary outcome [42] 0 0
Tmax of Glyco-OCA at Week 12
Timepoint [42] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 12
Primary outcome [43] 0 0
Ctrough of Glyco-OCA at Week 12
Timepoint [43] 0 0
24 hours post-dose at Week 12
Primary outcome [44] 0 0
AUC0-24h of Glyco-OCA at Week 12
Timepoint [44] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 12
Primary outcome [45] 0 0
Metabolite to Parent Ratio of AUC-0-24h (MRAUC) of Glyco-OCA at Week 12
Timepoint [45] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 12
Primary outcome [46] 0 0
Metabolite to Parent Ratio of Cmax (MRCmax) of Glyco-OCA at Week 12
Timepoint [46] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 12
Primary outcome [47] 0 0
Cmax of Glyco-OCA at Week 18
Timepoint [47] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 18
Primary outcome [48] 0 0
Tmax of Glyco-OCA at Week 18
Timepoint [48] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 18
Primary outcome [49] 0 0
Ctrough of Glyco-OCA at Week 18
Timepoint [49] 0 0
24 hours post-dose at Week 18
Primary outcome [50] 0 0
AUC0-24h of Glyco-OCA at Week 18
Timepoint [50] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 18
Primary outcome [51] 0 0
MRAUC of Glyco-OCA at Week 18
Timepoint [51] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 18
Primary outcome [52] 0 0
MRCmax of Glyco-OCA at Week 18
Timepoint [52] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 18
Primary outcome [53] 0 0
Cmax of Glyco-OCA at Week 24
Timepoint [53] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 24
Primary outcome [54] 0 0
Tmax of Glyco-OCA at Week 24
Timepoint [54] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 24
Primary outcome [55] 0 0
Ctrough of Glyco-OCA at Week 24
Timepoint [55] 0 0
24 hours post-dose at Week 24
Primary outcome [56] 0 0
AUC0-24h of Glyco-OCA at Week 24
Timepoint [56] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 24
Primary outcome [57] 0 0
MRAUC of Glyco-OCA at Week 24
Timepoint [57] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 24
Primary outcome [58] 0 0
MRCmax of Glyco-OCA at Week 24
Timepoint [58] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 24
Primary outcome [59] 0 0
Cmax of Glyco-OCA at Week 30
Timepoint [59] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 30
Primary outcome [60] 0 0
Tmax of Glyco-OCA at Week 30
Timepoint [60] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 30
Primary outcome [61] 0 0
Ctrough of Glyco-OCA at Week 30
Timepoint [61] 0 0
24 hours post-dose at Week 30
Primary outcome [62] 0 0
AUC0-24h of Glyco-OCA at Week 30
Timepoint [62] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 30
Primary outcome [63] 0 0
MRAUC of Glyco-OCA at Week 30
Timepoint [63] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 30
Primary outcome [64] 0 0
MRCmax of Glyco-OCA at Week 30
Timepoint [64] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 30
Primary outcome [65] 0 0
Cmax of Glyco-OCA at Week 48
Timepoint [65] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 48
Primary outcome [66] 0 0
Tmax of Glyco-OCA at Week 48
Timepoint [66] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 48
Primary outcome [67] 0 0
Ctrough of Glyco-OCA at Week 48
Timepoint [67] 0 0
24 hours post-dose at Week 48
Primary outcome [68] 0 0
AUC0-24h of Glyco-OCA at Week 48
Timepoint [68] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 48
Primary outcome [69] 0 0
MRAUC of Glyco-OCA at Week 48
Timepoint [69] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 48
Primary outcome [70] 0 0
MRCmax of Glyco-OCA at Week 48
Timepoint [70] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 48
Primary outcome [71] 0 0
Cmax of Tauro Conjugate of OCA (Tauro-OCA) at Week 12
Timepoint [71] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 12
Primary outcome [72] 0 0
Tmax of Tauro-OCA at Week 12
Timepoint [72] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 12
Primary outcome [73] 0 0
Ctrough of Tauro-OCA at Week 12
Timepoint [73] 0 0
24 hours post-dose at Week 12
Primary outcome [74] 0 0
AUC0-24h of Tauro-OCA at Week 12
Timepoint [74] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 12
Primary outcome [75] 0 0
MRAUC of Tauro-OCA at Week 12
Timepoint [75] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 12
Primary outcome [76] 0 0
MRCmax of Tauro-OCA at Week 12
Timepoint [76] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 12
Primary outcome [77] 0 0
Cmax of Tauro-OCA at Week 18
Timepoint [77] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 18
Primary outcome [78] 0 0
Tmax of Tauro-OCA at Week 18
Timepoint [78] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 18
Primary outcome [79] 0 0
Ctrough of Tauro-OCA at Week 18
Timepoint [79] 0 0
24 hours post-dose at Week 18
Primary outcome [80] 0 0
AUC0-24h of Tauro-OCA at Week 18
Timepoint [80] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 18
Primary outcome [81] 0 0
MRAUC of Tauro-OCA at Week 18
Timepoint [81] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 18
Primary outcome [82] 0 0
MRCmax of Tauro-OCA at Week 18
Timepoint [82] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 18
Primary outcome [83] 0 0
Cmax of Tauro-OCA at Week 24
Timepoint [83] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 24
Primary outcome [84] 0 0
Tmax of Tauro-OCA at Week 24
Timepoint [84] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 24
Primary outcome [85] 0 0
Ctrough of Tauro-OCA at Week 24
Timepoint [85] 0 0
24 hours post-dose at Week 24
Primary outcome [86] 0 0
AUC0-24h of Tauro-OCA at Week 24
Timepoint [86] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 24
Primary outcome [87] 0 0
MRAUC of Tauro-OCA at Week 24
Timepoint [87] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 24
Primary outcome [88] 0 0
MRCmax of Tauro-OCA at Week 24
Timepoint [88] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 24
Primary outcome [89] 0 0
Cmax of Tauro-OCA at Week 30
Timepoint [89] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 30
Primary outcome [90] 0 0
Tmax of Tauro-OCA at Week 30
Timepoint [90] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 30
Primary outcome [91] 0 0
Ctrough of Tauro-OCA at Week 30
Timepoint [91] 0 0
24 hours post-dose at Week 30
Primary outcome [92] 0 0
AUC0-24h of Tauro-OCA at Week 30
Timepoint [92] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 30
Primary outcome [93] 0 0
MRAUC of Tauro-OCA at Week 30
Timepoint [93] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 30
Primary outcome [94] 0 0
MRCmax of Tauro-OCA at Week 30
Timepoint [94] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 30
Primary outcome [95] 0 0
Cmax of Tauro-OCA at Week 48
Timepoint [95] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 48
Primary outcome [96] 0 0
Tmax of Tauro-OCA at Week 48
Timepoint [96] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 48
Primary outcome [97] 0 0
Ctrough of Tauro-OCA at Week 48
Timepoint [97] 0 0
24 hours post-dose at Week 48
Primary outcome [98] 0 0
AUC0-24h of Tauro-OCA at Week 48
Timepoint [98] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 48
Primary outcome [99] 0 0
MRAUC of Tauro-OCA at Week 48
Timepoint [99] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 48
Primary outcome [100] 0 0
MRCmax of Tauro-OCA at Week 48
Timepoint [100] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 48
Primary outcome [101] 0 0
Cmax of Glucuronide Metabolite of OCA (OCA-glucuronide) at Week 12
Timepoint [101] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 12
Primary outcome [102] 0 0
Tmax of OCA-glucuronide at Week 12
Timepoint [102] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 12
Primary outcome [103] 0 0
Ctrough of OCA-glucuronide at Week 12
Timepoint [103] 0 0
24 hours post-dose at Week 12
Primary outcome [104] 0 0
AUC0-24h of OCA-glucuronide at Week 12
Timepoint [104] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 12
Primary outcome [105] 0 0
MRAUC of OCA-glucuronide at Week 12
Timepoint [105] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 12
Primary outcome [106] 0 0
MRCmax of OCA-glucuronide at Week 12
Timepoint [106] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 12
Primary outcome [107] 0 0
Cmax of OCA-glucuronide at Week 18
Timepoint [107] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 18
Primary outcome [108] 0 0
Tmax of OCA-glucuronide at Week 18
Timepoint [108] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 18
Primary outcome [109] 0 0
Ctrough of OCA-glucuronide at Week 18
Timepoint [109] 0 0
24 hours post-dose at Week 18
Primary outcome [110] 0 0
AUC0-24h of OCA-glucuronide at Week 18
Timepoint [110] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 18
Primary outcome [111] 0 0
MRAUC of OCA-glucuronide at Week 18
Timepoint [111] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 18
Primary outcome [112] 0 0
MRCmax of OCA-glucuronide at Week 18
Timepoint [112] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 18
Primary outcome [113] 0 0
Cmax of OCA-glucuronide at Week 24
Timepoint [113] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 24
Primary outcome [114] 0 0
Tmax of OCA-glucuronide at Week 24
Timepoint [114] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 24
Primary outcome [115] 0 0
Ctrough of OCA-glucuronide at Week 24
Timepoint [115] 0 0
24 hours post-dose at Week 24
Primary outcome [116] 0 0
AUC0-24h of OCA-glucuronide at Week 24
Timepoint [116] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 24
Primary outcome [117] 0 0
MRAUC of OCA-glucuronide at Week 24
Timepoint [117] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 24
Primary outcome [118] 0 0
MRCmax of OCA-glucuronide at Week 24
Timepoint [118] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 24
Primary outcome [119] 0 0
Cmax of OCA-glucuronide at Week 30
Timepoint [119] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 30
Primary outcome [120] 0 0
Tmax of OCA-glucuronide at Week 30
Timepoint [120] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 30
Primary outcome [121] 0 0
Ctrough of OCA-glucuronide at Week 30
Timepoint [121] 0 0
24 hours post-dose at Week 30
Primary outcome [122] 0 0
AUC0-24h of OCA-glucuronide at Week 30
Timepoint [122] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 30
Primary outcome [123] 0 0
MRAUC of OCA-glucuronide at Week 30
Timepoint [123] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 30
Primary outcome [124] 0 0
MRCmax of OCA-glucuronide at Week 30
Timepoint [124] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 30
Primary outcome [125] 0 0
Cmax of OCA-glucuronide at Week 48
Timepoint [125] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 48
Primary outcome [126] 0 0
Tmax of OCA-glucuronide at Week 48
Timepoint [126] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 48
Primary outcome [127] 0 0
Ctrough of OCA-glucuronide at Week 48
Timepoint [127] 0 0
24 hours post-dose at Week 48
Primary outcome [128] 0 0
AUC0-24h of OCA-glucuronide at Week 48
Timepoint [128] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 48
Primary outcome [129] 0 0
MRAUC of OCA-glucuronide at Week 48
Timepoint [129] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 48
Primary outcome [130] 0 0
MRCmax of OCA-glucuronide at Week 48
Timepoint [130] 0 0
Pre-dose (30 minutes before administration) and 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours post-dose at Week 48
Primary outcome [131] 0 0
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Timepoint [131] 0 0
Baseline up to approximately 3 years
Secondary outcome [1] 0 0
Change From Baseline in the Model of End-stage Liver Disease (MELD) Score at Weeks 3, 6, 12, 18, 24, 30, 36, 42, and 48; and Extension Months 3, 6, 9, 12, and 15
Timepoint [1] 0 0
Baseline, Weeks 3, 6, 12, 18, 24, 30, 36, 42, and 48; and Extension Months 3, 6, 9, 12, and 15
Secondary outcome [2] 0 0
Change From Baseline in MELD-Sodium (Na) Score at Weeks 3, 6, 12, 18, 24, 30, 36, 42, and 48; and Extension Months 3, 6, 9, 12, and 15
Timepoint [2] 0 0
Baseline, Weeks 3, 6, 12, 18, 24, 30, 36, 42, and 48; and Extension Months 3, 6, 9, 12, and 15
Secondary outcome [3] 0 0
Change From Baseline in Child-Pugh Score at Day 1, Weeks 6, 12, 18, 24, 30, 36, and 48; and Extension Months 3, 6, 9, 12, and 15
Timepoint [3] 0 0
Baseline, Day 1, Weeks 6, 12, 18, 24, 30, 36, and 48; and Extension Months 3, 6, 9, 12, and 15
Secondary outcome [4] 0 0
Number of Participants by Child-Pugh Score Component Category (Ascites Categories)
Timepoint [4] 0 0
Day 1, Weeks 6, 12, 18, 24, 30, 36, and 48; and Extension Months 3, 6, 9, 12, and 15
Secondary outcome [5] 0 0
Number of Participants by Child-Pugh Score Component Category (Prothrombin Time Categories)
Timepoint [5] 0 0
Day 1, Weeks 6, 12, 18, 24, 30, 36, and 48; and Extension Months 3, 6, 9, 12, and 15
Secondary outcome [6] 0 0
Number of Participants by Child-Pugh Score Component Category (Serum Albumin Categories)
Timepoint [6] 0 0
Day 1, Weeks 6, 12, 18, 24, 30, 36, and 48; and Extension Months 3, 6, 9, 12, and 15
Secondary outcome [7] 0 0
Number of Participants by Child-Pugh Score Component Category (Total Bilirubin Categories)
Timepoint [7] 0 0
Day 1, Weeks 6, 12, 18, 24, 30, 36, and 48; and Extension Months 3, 6, 9, 12, and 15
Secondary outcome [8] 0 0
Number of Participants by Child-Pugh Score Component Category (Hepatic Encephalopathy Categories)
Timepoint [8] 0 0
Day 1, Weeks 6, 12, 18, 24, 30, 36, and 48; and Extension Months 3, 6, 9, 12, and 15
Secondary outcome [9] 0 0
Change From Baseline in Total Bilirubin at Weeks 3, 6, 12, 18, 24, 30, 36, 42, and 48; and Extension Months 3, 6, 9, 12, and 15
Timepoint [9] 0 0
Baseline, Weeks 3, 6, 12, 18, 24, 30, 36, 42, and 48; and Extension Months 3, 6, 9, 12, and 15
Secondary outcome [10] 0 0
Change From Baseline in Direct Bilirubin at Weeks 3, 6, 12, 18, 24, 30, 36, 42, and 48; and Extension Months 3, 6, 9, 12, and 15
Timepoint [10] 0 0
Baseline, Weeks 3, 6, 12, 18, 24, 30, 36, 42, and 48; and Extension Months 3, 6, 9, 12, and 15
Secondary outcome [11] 0 0
Change From Baseline in Alkaline Phosphatase at Weeks 3, 6, 12, 18, 24, 30, 36, 42, and 48; and Extension Months 3, 6, 9, 12, and 15
Timepoint [11] 0 0
Baseline, Weeks 3, 6, 12, 18, 24, 30, 36, 42, and 48; and Extension Months 3, 6, 9, 12, and 15
Secondary outcome [12] 0 0
Change From Baseline in Alanine Aminotransferase at Weeks 3, 6, 12, 18, 24, 30, 36, 42, and 48; and Extension Months 3, 6, 9, 12, and 15
Timepoint [12] 0 0
Baseline, Weeks 3, 6, 12, 18, 24, 30, 36, 42, and 48; and Extension Months 3, 6, 9, 12, and 15
Secondary outcome [13] 0 0
Change From Baseline in Aspartate Aminotransferase at Weeks 3, 6, 12, 18, 24, 30, 36, 42, and 48; and Extension Months 3, 6, 9, 12, and 15
Timepoint [13] 0 0
Baseline, Weeks 3, 6, 12, 18, 24, 30, 36, 42, and 48; and Extension Months 3, 6, 9, 12, and 15
Secondary outcome [14] 0 0
Change From Baseline in Gamma Glutamyl Transferase at Weeks 3, 6, 12, 18, 24, 30, 36, 42, and 48; and Extension Months 3, 6, 9, 12, and 15
Timepoint [14] 0 0
Baseline, Weeks 3, 6, 12, 18, 24, 30, 36, 42, and 48; and Extension Months 3, 6, 9, 12, and 15
Secondary outcome [15] 0 0
Change From Baseline in Prothrombin INR at Weeks 3, 6, 12, 18, 24, 30, 36, 42, and 48; and Extension Months 3, 6, 9, 12, and 15
Timepoint [15] 0 0
Baseline, Weeks 3, 6, 12, 18, 24, 30, 36, 42, and 48; and Extension Months 3, 6, 9, 12, and 15
Secondary outcome [16] 0 0
Change From Baseline in Creatinine at Weeks 3, 6, 12, 18, 24, 30, 36, 42, and 48; and Extension Months 3, 6, 9, 12, and 15
Timepoint [16] 0 0
Baseline, Weeks 3, 6, 12, 18, 24, 30, 36, 42, and 48; and Extension Months 3, 6, 9, 12, and 15
Secondary outcome [17] 0 0
Change From Baseline in Albumin at Weeks 3, 6, 12, 18, 24, 30, 36, 42, and 48; and Extension Months 3, 6, 9, 12, and 15
Timepoint [17] 0 0
Baseline, Weeks 3, 6, 12, 18, 24, 30, 36, 42, and 48; and Extension Months 3, 6, 9, 12, and 15
Secondary outcome [18] 0 0
Change From Baseline in Platelets at Weeks 3, 6, 12, 18, 24, 30, 36, 42, and 48; and Extension Months 3, 6, 9, 12, and 15
Timepoint [18] 0 0
Baseline, Weeks 3, 6, 12, 18, 24, 30, 36, 42, and 48; and Extension Months 3, 6, 9, 12, and 15
Secondary outcome [19] 0 0
Change From Baseline in Total Bile Acids Concentration at Weeks 6, 12, 18, 24, 30, 36, and 48; and Extension Month 3
Timepoint [19] 0 0
Baseline, Weeks 6, 12, 18, 24, 30, 36, and 48; and Extension Month 3
Secondary outcome [20] 0 0
Change From Baseline in Total Endogenous Bile Acids Concentration at Weeks 6, 12, 18, 24, 30, 36, and 48; and Extension Month 3
Timepoint [20] 0 0
Baseline, Weeks 6, 12, 18, 24, 30, 36, and 48; and Extension Month 3
Secondary outcome [21] 0 0
Change From Baseline in 7a-hydroxy-4-cholesten-3-one (C4) at Weeks 6, 12, 18, 24, 30, 36, and 48; and Extension Month 3
Timepoint [21] 0 0
Baseline, Weeks 6, 12, 18, 24, 30, 36, and 48; and Extension Month 3
Secondary outcome [22] 0 0
Change From Baseline in Fibroblast Growth Factor-19 (FGF-19) Concentrations at Weeks 6, 12, 18, 24, 30, 36, and 48; and Extension Month 3
Timepoint [22] 0 0
Baseline, Weeks 6, 12, 18, 24, 30, 36, and 48; and Extension Month 3

Eligibility
Key inclusion criteria
1. A definite or probable diagnosis of PBC (consistent with American Association for the Study of Liver Diseases [AASLD] and European Association for the Study of the Liver [EASL] Practice Guidelines, defined as having =2 of the following 3 diagnostic factors:

* History of elevated alkaline phosphatase (ALP) levels for at least 6 months
* Positive antimitochondrial antibody (AMA) titer or if AMA negative or low titer (=1:80), PBC specific antibodies (anti-glycoprotein 210 [GP210] and/or anti-SP100) and/or antibodies against the major M2 components (E2 component of mitochondrial pyruvate dehydrogenase complex [PDC-E2], 2-oxo-glutaric acid dehydrogenase complex)
* Liver biopsy consistent with PBC (collected at any time prior to Screening)
2. Evidence of cirrhosis including at least one of the following:

* Biopsy results consistent with PBC Stage 4
* Liver stiffness as assessed by Transient Elastography (TE) Median Value =16.9 kilopascals (kPa)
* Clinical evidence in the absence of acute liver failure consistent with cirrhosis including: gastroesophageal varices, ascites, radiological evidence of cirrhosis (nodular liver or enlargement of portal vein and splenomegaly)
* Combined low platelet count (<140,000/cubic millimeter [mm^3]) with

* persistent decrease in serum albumin, or
* elevation in prothrombin time/international normalized ratio (INR) (not due to antithrombotic agent use), or
* elevated bilirubin (2*upper limit of normal [ULN])
3. Satisfy the criteria of the modified Child-Pugh (CP) classification for hepatic impairment during Screening:

* Moderate: CP-B (Scores 7 to 9) or
* Severe: CP-C (Scores 10 to 12)
4. Model of end-stage liver disease (MELD) score of 6 to 24 at Screening
5. Taking ursodeoxycholic acid (UDCA) for at least 12 months (stable dose for =3 months) prior to Day 1, or unable to tolerate or unresponsive to UDCA (no UDCA for =3 months)
Minimum age
18 Years
Maximum age
85 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Non-cirrhotic or cirrhotic CP-A (Mild; Score 5 to 6)
2. History of liver transplant or organ transplant
3. History of alcohol or drug abuse within 12 months prior to Screening
4. Hepatic encephalopathy (as defined by a West Haven score of =2
5. History or presence of other concomitant liver diseases including:

* Hepatitis C virus infection and ribonucleic acid (RNA) positive
* Active hepatitis B infection; however, participants who have seroconverted (hepatitis B surface antigen and hepatitis B e antigen negative) may be included in this study after consultation with the medical monitor
* Primary sclerosing cholangitis
* Alcoholic liver disease
* Definite autoimmune liver disease or overlap hepatitis
* Gilbert's Syndrome
6. In the opinion of the Investigator, fluctuating or rapidly deteriorating hepatic function prior to randomization

Other inclusion/exclusion criteria may apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 4
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
22/06/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
9/07/2021
Sample size
Target
Accrual to date
Final
22
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Royal Prince Alfred Hospital - Camperdown
Recruitment hospital [2] 0 0
Nepean Hospital - Kingswood
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2747 - Kingswood
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Maryland
Country [4] 0 0
United States of America
State/province [4] 0 0
Michigan
Country [5] 0 0
United States of America
State/province [5] 0 0
Missouri
Country [6] 0 0
United States of America
State/province [6] 0 0
Ohio
Country [7] 0 0
United States of America
State/province [7] 0 0
Pennsylvania
Country [8] 0 0
United States of America
State/province [8] 0 0
Texas
Country [9] 0 0
Argentina
State/province [9] 0 0
Buenos Aires
Country [10] 0 0
Argentina
State/province [10] 0 0
Caba
Country [11] 0 0
Argentina
State/province [11] 0 0
Ciudad Autonoma de Buenos Aire
Country [12] 0 0
Argentina
State/province [12] 0 0
Mendoza
Country [13] 0 0
Argentina
State/province [13] 0 0
Pilar
Country [14] 0 0
Argentina
State/province [14] 0 0
Rosario
Country [15] 0 0
Belgium
State/province [15] 0 0
Brussels
Country [16] 0 0
Belgium
State/province [16] 0 0
Edegem
Country [17] 0 0
Belgium
State/province [17] 0 0
Leuven
Country [18] 0 0
Brazil
State/province [18] 0 0
Belo Horizonte
Country [19] 0 0
Brazil
State/province [19] 0 0
Rio Grande
Country [20] 0 0
Brazil
State/province [20] 0 0
São Paulo
Country [21] 0 0
Canada
State/province [21] 0 0
Toronto
Country [22] 0 0
Estonia
State/province [22] 0 0
Tallinn
Country [23] 0 0
Estonia
State/province [23] 0 0
Tartu
Country [24] 0 0
Germany
State/province [24] 0 0
Leipzig
Country [25] 0 0
Hungary
State/province [25] 0 0
Bekescsaba
Country [26] 0 0
Italy
State/province [26] 0 0
MB
Country [27] 0 0
Italy
State/province [27] 0 0
Modena
Country [28] 0 0
Lithuania
State/province [28] 0 0
Kaunas
Country [29] 0 0
Lithuania
State/province [29] 0 0
Klaipeda
Country [30] 0 0
Lithuania
State/province [30] 0 0
Vilnius
Country [31] 0 0
Spain
State/province [31] 0 0
Barcelona
Country [32] 0 0
Spain
State/province [32] 0 0
Sevilla
Country [33] 0 0
Spain
State/province [33] 0 0
Valencia

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Intercept Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This Phase 4, randomized, double-blind, placebo-controlled study will evaluate the pharmacokinetics (PK) and safety of OCA treatment in participants with PBC and moderate to severe hepatic impairment over a 48-week treatment period. Participants who have completed their 48-week double blind treatment period will continue double-blind treatment until all randomized participants have completed their 48-week treatment period and the database for that period is locked. An open-label extension study in which all participants receive OCA will be considered following review of blinded safety and PK data.
Trial website
https://clinicaltrials.gov/study/NCT03633227
Trial related presentations / publications
Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ; American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology. 2009 Jul;50(1):291-308. doi: 10.1002/hep.22906. No abstract available.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009 Aug;51(2):237-67. doi: 10.1016/j.jhep.2009.04.009. Epub 2009 Jun 6. No abstract available.
Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, Weissenborn K, Wong P. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014 Aug;60(2):715-35. doi: 10.1002/hep.27210. Epub 2014 Jul 8. No abstract available.
Public notes

Contacts
Principal investigator
Name 0 0
Steven Shiff, M.D.
Address 0 0
Intercept Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT03633227